French based Sanofi and its U.S. partner Regeneron Pharma set to win approval for the first systemic therapy for severe atopic dermatitis (AD).
Sanofi, a French drug manufacturer, and its U.S. partner, Regeneron Pharmaceuticals, are set to win approval in the U.S. for the launch of their keenly awaited eczema drug – dupilumab.
According to analysts the market for this new drug stands at around $3 billion-a-year.
Lantus, Sanofi’s top seller is facing stiff competition in the flagging diabetes market. Dupilumab could be its silver lining which could lift sales.
Both companies have stated that the U.S. FDA has accepted dupilumab for a priority review for the treatment of atopic dermatitis (AD), a skin inflammation also known as atopic eczema. By March 29, the FDA will decide on this application.
Sanofi’s new drug is an injectable antibody, seen by investors as the company’s most promising assets in its pipeline given the success it has had on clinical trials.
Significantly, dupilumab could be the first systemic therapy for severe AD.
Dupilumab is also being developed for severe asthma. However in that segment it will face competition from GlaxoSmithKline’s Nucala and Teva’s Cinqair.
According to Thomson Reuters Cortellis, by 2021, dupilumab’s annual turnover could be as much as $3.0 billion.
Categories: Creativity, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy
manageria.biz 
Leave a comment